Connor, Clark & Lunn Investment Management Ltd.

Position in TBPH — Theravance Biopharma, Inc.

CIK 1596800 VANCOUVER, A1

Position in TBPH

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,053,897

-$999,626 QoQ

Shares Held

179,641

-28.1% QoQ

Ownership

0.346%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#30

of 179 holders

Holding Since

Sep 2021

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $648,992,404 across 104 Biotechnology names. TBPH ranks #40 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,053,897	179,641	-28.1%	Shares	Sole	2026-08-13
2026-03-31	$4,053,523	249,755	+12.7%	Shares	Sole	2026-05-11
2025-12-31	$4,147,296	221,662	+26.8%	Shares	Sole	2026-02-10
2025-09-30	$2,552,620	174,837	+208.8%	Shares	Sole	2025-11-13
2025-06-30	$624,441	56,613	+253.3%	Shares	Sole	2025-08-07
2024-06-30	$135,875	16,023	-60.4%	Shares	Sole	2024-08-09
2022-03-31	$386,960	40,477	+22.5%	Shares	Sole	2022-05-12
2021-12-31	$365,025	33,034	-25.3%	Shares	Sole	2022-02-10
2021-09-30	$327,353	44,237	—	Shares	Sole	2021-11-12
No filing history on record for this holder in this stock.